Interleukin-6 in Renal Cell Carcinoma

Tsukamoto, Taiji; Kumamoto, Yoshiaki; Miyao, Noriomi; Masumori, Naoya; Takahashi, Atsushi; Yanase, Masahiro

doi:10.1016/s0022-5347(17)37026-x

Cited by 91 publications

(50 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased serum levels of IL-6, found in a large percentage of patients, correlated with tumor size and grade, and IL-6 pretreatment serum levels correlated as an independent factor with prognosis, similarly as in many solid tumors, including renal cancer, 52 colorectal cancer, 19,53 lung cancer, 54 gynecological cancers 55 and melanoma. 25 Tamm et al have shown that IL-6 may directly promote tumor cells motility and invasion.…”

Section: Cytokine Serum Levels During Follow-upmentioning

confidence: 85%

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Rutkowski

Kamińska

Kowalska

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated the correlations between serum levels of selected proinflammatory, hematopoietic and angiogenic cytokines and soluble cytokine receptors with the clinicopathological features and prognosis in soft tissue sarcoma patients. Serum levels of 9 cytokines (TNF␣, IL-1ra, IL-6, IL-8, IL-10, M-CSF, G-CSF, VEGF, bFGF) and 4 free cytokine receptors (sIL-2R␣, sIL-6R, TNFRI, TNFRII) were measured by means of an enzyme-linked immunoadsorbent assay kit in 156 soft tissue sarcoma patients before the treatment and in 50 healthy controls. Serum levels of 10 cytokines and cytokine receptors were also assayed during patients' follow-up after the treatment. Significantly elevated pretreatment serum levels of 11/13 cytokines and cytokine receptors were found in sarcoma patients, as compared to healthy controls.

show abstract

Section: Cytokine Serum Levels During Follow-upmentioning

confidence: 85%

Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosis

Rutkowski

Kamińska

Kowalska

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Blay et al (1992) reported that serum IL-6 was positive in 48% of patients with RCC. Tsukamoto et al (1992) reported that it was positive in 25% and Hamao et al (1994) reported that it was positive in 53%. In our study, serum IL-6 could be detected in all patients in the control group and RCC group by using a highly sensitive ELISA kit in our present study.…”

Section: Discussionmentioning

confidence: 99%

“…They also reported that the presence of high pretreatment serum IL-6 levels inversely correlated to the response to IL-2 and to survival after immunotherapy with IL-2 in patients with RCC (Blay et al, 1990). Tsukamoto et al (1992) reported that serum IL-6 was detected in 18 out of 71 patients (25%). They indicated that although IL-6 level did not directly correlate with tumour volume and differentiation grade of the carcinoma, the positive rate increased with progression of the stage, and that serum IL-6 level affected the 5-year survival of patients without distant metastasis.…”

mentioning

confidence: 99%

Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma

et al. 2002

View full text Add to dashboard Cite

As regulators of malignant cell behaviour and communication with stroma, cytokines have proved useful in understanding cancer biology and developing novel therapies. In renal cell carcinoma, patients with inflammatory reactions are known to have poor prognosis. In order to elucidate the relation between renal cell carcinoma and the host, serum levels of inflammatory cytokines, interleukin-6, tumour necrosis factor a, interleukin-1b, were measured. One hundred and twenty-two patients with renal cell carcinoma and 21 healthy control subjects were studied, and serum cytokine levels were measured using a highly sensitive ELISA kit. As a result, in the control group, interleukin-6, tumour necrosis factor a and interleukin-1b levels were 1.79+2.03, 2.74+0.94 and 0.16+0.17 pg ml 71, respectively. In the renal cell carcinoma patients, they were 8.91+13.12, 8.44+4.15 and 0.53+0.57 pg ml 71 , respectively, and significantly higher. In the comparison of stage, interleukin-6 level was significantly higher in the stage IV group compared to the other stage groups including the control group, while tumour necrosis factor a level was significantly higher in each stage group compared to the control group. As for grade, interleukin-6 level was significantly higher in the grade 3 group compared to the control, grade 1 and grade 2 groups, while tumour necrosis factor a level was significantly higher in each grade group compared to the control group. All cytokines had a positive correlation with tumour size. In regard to the correlation with CRP, all cytokines had a positive correlation with CRP, while interleukin-6 had a particularly strong correlation. In conclusion, interleukin-6 may be one of the factors for the poor prognosis of patients with renal cell carcinoma. In addition, tumour necrosis factor a may be useful in the early diagnosis of renal cell carcinoma and post-operative follow-up.

show abstract

“…IL-6 is also reported to be produced by other epithelial tumors [5]. Increased serum IL-6 levels have been found in patients with multiple myeloma [6], renal cell carcinoma [7], bladder carcinoma [8], head and neck cancer [9], ovarian cancer [10], and cholangiocarcinoma [11].…”

Section: Introductionmentioning

confidence: 99%